Skip to main content

Deciphering Benign and Malignant Perineuriomas: A Comparative Epigenomic and Genomic Study With Hybrid and Malignant Peripheral Nerve Tumors

In brief

Ten of 18 malignant perineuriomas resembled undifferentiated sarcoma epigenetically

DNA methylation profiling separated benign perineuriomas from tumor mimics, but 10 of 18 malignant cases looked epigenetically closer to undifferentiated sarcoma than to benign perineuriomas or malignant peripheral nerve sheath tumors. The malignant tumors also had varied genomic changes; with only 21 months of median follow-up, it remains unclear whether they represent one disease or several high-grade sarcoma types.

Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (Q1)
Published
12 November 2026
Study design
Unclassified
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Ashley Patton, Carina A Dehner, Travis Hattery, Mark J Chen, Sheila Shurtleff, Elizabeth M Azzato, et al.
PMID
43020433
DOI
10.1016/j.modpat.2026.101114

Why clinicians should know about it

  • Picked for Pathology and Forensic Medicine (top studies of the week, 15 November 2026): Methylation profiling refines classification of diagnostically challenging nerve sheath tumors

Abstract

BACKGROUND: Perineuriomas are uncommon benign peripheral nerve sheath tumors composed of perineurial cells. Conventional perineurioma and sclerosing variants overlap histologically with several soft tissue tumors, including low-grade fibromyxoid sarcoma, dermatofibrosarcoma protuberans, and sclerosing epithelioid fibrosarcoma. EMA and GLUT1 immunohistochemistry lack specificity, and recurrent genetic alterations have not been consistently identified. Malignant perineuriomas are exceptionally rare, may mimic YAP1::KMT2A-rearranged and TRAF7-mutant sarcomas, and remain poorly defined relative to malignant peripheral nerve sheath tumors (MPNST). We investigated whether DNA methylation profiling could refine classification and clarify epigenetic relationships with potential mimics. DESIGN: A multi-institutional cohort included conventional perineurioma (23), sclerosing perineurioma (9), pseudolipoblastic perineurioma (1), hybrid schwannoma-perineurioma (12), and malignant perineurioma (18). DNA methylation profiling was performed using the Illumina Infinium EPICv2 array. Comparative genomic profiling was also performed in 7 malignant perineuriomas and 16 MPNSTs. RESULTS: Conventional and sclerosing perineuriomas displayed a unified, distinct DNA methylation profile relative to mesenchymal mimics. Twenty-five percent of benign perineuriomas harbored mutually exclusive NF1 or NF2 deletions. Hybrid schwannoma-perineuriomas overlapped epigenetically with neurofibromas, whereas perineuriomas demonstrated hypomethylation of genes involved in cell junction/cell-matrix interactions and hypermethylation of genes involved in nervous system development. Patients with malignant perineurioma were significantly older and had larger tumors than those with benign variants or hybrid schwannoma-perineurioma. At median 21-month follow-up, 3 had local recurrence, 1 presented with multiple pleural masses, and 2 died of progressive disease. Most malignant perineuriomas (10/18) did not cluster with benign perineuriomas or MPNST but instead showed closer epigenetic similarity to undifferentiated sarcoma. They also exhibited significantly greater genome-wide copy number variation and heterogeneous genomic profiles, including loss-of-function PTPRD, TP53, ATM, and RB1 alterations. CONCLUSION: Perineuriomas are epigenetically distinct. Hybrid schwannoma-perineuriomas are epigenetically related to neurofibromas. Histologically diagnosed malignant perineuriomas may represent biologically heterogeneous high-grade sarcomas rather than a distinct perineurial neoplasm.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.